EUVIMEDEUVIMED entdecken
Crossref

Microneedle-Based Transdermal Delivery of Antidiabetic Agents: Progress, Challenges, and Emerging Directions

Kasim Gulamaliwala, Janhavi Bendale, Manisha Lalan

Biomedical Materials & Devices · 11.11.2026

DOI: 10.1007/s44174-026-00799-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Materials & Devices, online erschienen am 11.11.2026. Verfasst von Kasim Gulamaliwala und 2 weiteren Autor:innen. Die Arbeit nennt 138 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The WHO estimates that over 500 million people worldwide are diagnosed with diabetes mellitus, and its prevalence is expected to increase to 12.2% by 2045. Current treatment options include oral and injectable medications such as insulin and glucagon-like peptide-1 (GLP-1) receptor agonists, which have several challenges associated with them, including degradation in the gastrointestinal tract and low patient compliance. An alternative approach for transdermal administration of drugs may be through the use of Microneedle (MN) systems, which create temporary microchannels in the skin to allow passage of both small molecules and larger biologics to the viable layer of skin. This review will briefly discuss the evolution of MN systems and critically navigate the recent advances that have been made in antidiabetic MN systems. The MN systems have been reported to offer benefits pertaining to drug absorption and glycaemic control in preclinical models. The article also reviews next-generation smart MN technologies, specifically, glucose-responsive MN systems, coupled with artificial pancreas designs for glucose biosensing and insulin delivery. Future research trends indicate interest towards 4D printing of MN and the creation of biodegradable devices to improve diabetes management. Despite all the intriguing research in the field, MN systems have seen limited commercial success as challenges exist such as limited drug load, volume limits, manufacturing inconsistency, and stringent regulatory mandates. The review discusses the roadmap for possible clinical deployment of MN systems in effective diabetes management. Graphical Abstract

Zitieren

APA

Gulamaliwala, K., Bendale, J., & Lalan, M. (2026). Microneedle-Based Transdermal Delivery of Antidiabetic Agents: Progress, Challenges, and Emerging Directions. Biomedical Materials & Devices. https://doi.org/10.1007/s44174-026-00799-7

Vancouver

Gulamaliwala K, Bendale J, Lalan M. Microneedle-Based Transdermal Delivery of Antidiabetic Agents: Progress, Challenges, and Emerging Directions. Biomedical Materials & Devices. 2026. doi:10.1007/s44174-026-00799-7

BibTeX
@article{Gulamaliwala2026,
  author = {Gulamaliwala, Kasim and Bendale, Janhavi and Lalan, Manisha},
  title = {Microneedle-Based Transdermal Delivery of Antidiabetic Agents: Progress, Challenges, and Emerging Directions},
  journal = {Biomedical Materials & Devices},
  year = {2026},
  doi = {10.1007/s44174-026-00799-7}
}
Kostenlos starten →